DropScreen, ViewAllergy39 Not Equally Effective for Detecting Allergens
MONDAY, July 14, 2025 -- DropScreen (DS) and ViewAllergy39 (VA) are not equally effective for detecting specific immunoglobulin (Ig) E involved in pollinosis, according to a study recently published online in the Journal of Immunoassay and Immunochemistry.
Tomohiro Ono, Ph.D., from Ono Otolaryngology Clinic in Kakogawa, Japan, and colleagues compared performance of the DS point-of-care test with that of VA, a laboratory test for identifying causative aeroallergens, in patients with pollinosis. Sera were obtained from 70 Japanese outpatients with pollinosis.
The researchers found that for the 17 allergens included in the study, the average positivity rates were 20.8 and 26.6 percent for DS and VA, respectively. For Japanese cypress, the DS positive rate was 10-fold lower than that of VA. For Japanese cedar, Moth, and Aspergillus fumigatus, clear discrepancies were seen in detection rates between VA and DS. Inhibition tests on discrepant sera confirmed that specific IgE toward these allergens could be accurately measured using VA.
"Our findings confirm that not all specific IgE tests are equally powerful in aiding clinicians in the identification of allergens associated with pollinosis," the authors write. "Further studies of the potential impact of testing performance differences on diagnostic workup and subsequent therapy selection are needed."
Several authors disclosed ties to Thermo Fisher Diagnostics, which funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Cancer Survival Lower in Rural Areas
WEDNESDAY, Oct. 1, 2025 -- Five-year cancer survival rates for each stage of cancer (localized, regional, and distant) is lower in nonmetropolitan areas for Black and White...
Loss of Smell May Linger After COVID-19
WEDNESDAY, Oct. 1, 2025 -- Self-reported change or loss in smell or taste is an accurate signal of verified hyposmia after COVID-19, although there is also a high rate of hyposmia...
Elderly Patients Benefit From Screening Mammography
WEDNESDAY, Oct. 1, 2025 -- Patients with breast cancer diagnosed at 80 years of age or older who received screening mammography present with earlier-stage disease and have better...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.